Asceneuron Joins Critical Path for Alzheimer's Disease Consortium

Asceneuron SA Switzerland United States of America California

Consortium brings together industry, academic, and regulatory experts to advance research and bridge gaps in drug development targeting Alzheimer's diseaseAsceneuron to contribute its expertise in neurodegenerative disease to advance biomarkers for drug development in Alzheimer's diseaseView original content:https://www.prnewswire.co.uk/news-releases/asceneuron-joins-critical-path-for-alzheimers-disease-consortium-302098499.html